The acute coronary syndrome (ACS) market is projected to grow beyond $12bn by 2022 at a compound annual growth rate of 4.6% steered by the launch of new lipid-targeting therapies, says a GlobalData report.
Titled ‘PharmaPoint: Acute Coronary Syndrome – Global Drug Forecast and Market Analysis to 2025’, the report states that the market will grow strongly from $7.8bn in 2015 backed by new lipid-targeting therapies for statin-intolerant patients.
The treatment will also be effective for those needing additional lowering of low-density lipoprotein C (LDL-C), along with statin therapy.
Entry of first proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors, Repatha (evolocumab) and Praluent (alirocumab) by 2016 and the launch of ETC-1002 by 2021, as well as a rise in the number of ACS incidents will fuel market growth.
A recurrence in ACS cases in patients with clinical atherosclerotic cardiovascular disease has been blamed on the available standard of care therapies that fail to achieve the guideline recommended levels of LDL-C. This is set to change with the launch of PCSK9 inhibitors Repatha and Praluent that have proved to be effective during their Phase III trials over placebo, with a 57% and 58% reduction in LDL-C from baseline respectively.
Another revolutionary drug, Esperion’s ETC-1002, is also expected to alter the ACS landscape with greater proven efficacy in Phase IIb studies. Oral, lipid-lowering drug ETC-1002 is considered to gain popularity for treating patients who are statin-intolerant.
Michela J. McMullan, Ph.D. GlobalData’s analyst covering cardiovascular and metabolic disorders, explains, “Generally speaking, the ACS market is a highly lucrative area for pharmaceutical companies to invest in drug development.
"Historically, Merck & Co. was the leading innovator in this space, boasting a multitude of therapies to combat atherosclerosis, such as the first-in-class statin Mevacor (lovastatin), as well as Zocor (simvastatin) and the cholesterol absorption inhibitor Zetia (ezetimibe).”
The GlobalData report also states that Merck’s leadership in the market will be threatened by the imminent patent loss between 2016 and 2020. Amgen and Sanofi / Regeneron are expected to emerge as the leaders in the lipid-lowering segment due to their newly launched PCSK9 inhibitors.